A robust, clinical-trial and publication evidence base supports use of the OrganOx metra®
To date, hundreds of donor livers have been studied in normothermic machine perfusion trials around the world, including 220 livers that formed the Consortium for Organ Preservation in Europe (COPE) randomised controlled trial published in Nature in April 2018.1 With clinical trials taking place across Europe and North America, the metra has an extensive evidence base.
Key trials and publications are summarised below.
A back-to-base experience of human normothermic ex situ liver perfusion: does the chill kill?
Bral M, Dajani K, Leon Izquierdo D et al. Liver Transpl. 2019;25:848–58.
A nonrandomised pilot study assessing whether the OrganOx metra can be used with a back-to-base model without impacting patient outcomes.
Liver transplantation with a normothermic machine preserved fatty nonagenarian liver: A case report
Manzia TM, Toti L, Quaranta C, et al. Int J Surg Rep. 2019;57:163–6.
This case report details how functional assessment of a nonagenarian liver with the OrganOx metra resulted in successful transplantation.
Liver transplantation from non-heart beating donors: Current status and future prospects.
Reddy S, Zivetti M, Brockmann J, McClaren A and Friend PJ – Liver Transplantation (2019) 10 1223-1232.
Transient cold storage prior to normothermic liver perfusion may facilitate adoption of a novel technology
Ceresa CDL, Nasralla D, Watson CJE, et al. Liver Transpl. 2019; [Epub ahead of print].
This multi-centre prospective study included 31 livers for transplantation and demonstrated that the OrganOx metra could be successfully used to extend the preservation of donor livers after a period of static cold storage without impacting patient outcomes.
A randomized trial of normothermic preservation in liver transplantation
Nasralla D, Coussios CC, Mergental H, et al. Consortium for Organ Preservation in Europe. Nature. 2018;557(7703):50–56.
The first randomised controlled trial comparing machine perfusion technology with static cold storage in human liver transplantation. In this trial, the OrganOx metra was transported to and from the donor centre to minimise cold storage time.
Compared with static cold storage, the OrganOx metra achieved a 50% lower level of graft injury despite a 50% lower rate of organ discard and a 54% longer mean preservation time.
Want to know more about the metra?
If you would like to know more about the metra and how it may benefit your liver transplantation unit, click ‘Contact Us’ and a member of the OrganOx team will be in touch.